PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Condition(s):Perihilar CholangiocarcinomaLast Updated:May 9, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Perihilar CholangiocarcinomaLast Updated:May 9, 2023Recruiting
Condition(s):Cholangiocarcinoma; Surgery–ComplicationsLast Updated:July 1, 2019Completed
Condition(s):Perihilar CholangiocarcinomaLast Updated:October 27, 2022Recruiting
Condition(s):Perihilar CholangiocarcinomaLast Updated:November 30, 2023Recruiting
Condition(s):Portal Vein Occlusion; Cholangiocarcinoma, Perihilar; Hepatocellular Carcinoma; Liver; Hypertrophy, AcuteLast Updated:June 17, 2020Unknown status
Condition(s):Perihilar CholangiocarcinomaLast Updated:May 25, 2023Recruiting
Condition(s):Klatskin TumorLast Updated:January 26, 2021Completed
Condition(s):Perihilar CholangiocarcinomaLast Updated:June 2, 2022Completed
Condition(s):Perihilar Cholangiocarcinoma; Klatskin Tumor; Bile Duct CancerLast Updated:December 13, 2023Recruiting
Condition(s):Biliary Tract Cancer; Portal Vein EmbolizationLast Updated:January 25, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.